According to Zacks, “Armata Pharmaceuticals Inc. is a biotechnology company. It is focused on the development of bacteriophage therapeutics for antibiotic-resistant infections using its proprietary bacteriophage-based technology. The company’s principal product candidate consist AP-SA01, targets Staphylococcus aureus including multidrug-resistant strains. It is also developing and advancing a pipeline of synthetic phage candidates, including a synthetic phage for Pseudomonas aeruginosa. Armata Pharmaceuticals Inc., formerly known as AmpliPhi Biosciences Corporation, is based in Marina del Rey, California. “
Shares of ARMP opened at $4.25 on Wednesday. Armata Pharmaceuticals has a 52 week low of $2.82 and a 52 week high of $6.49. The stock has a market capitalization of $153.47 million, a P/E ratio of -4.25 and a beta of 1.06.
A number of large investors have recently modified their holdings of ARMP. Susquehanna International Group LLP acquired a new position in Armata Pharmaceuticals in the 4th quarter valued at approximately $66,000. Dimensional Fund Advisors LP acquired a new position in Armata Pharmaceuticals in the 4th quarter valued at approximately $72,000. BlackRock Inc. increased its position in Armata Pharmaceuticals by 928.0% in the 3rd quarter. BlackRock Inc. now owns 20,571 shares of the company’s stock valued at $74,000 after acquiring an additional 18,570 shares during the period. Northern Trust Corp acquired a new position in Armata Pharmaceuticals in the 1st quarter valued at approximately $95,000. Finally, Vanguard Group Inc. increased its position in Armata Pharmaceuticals by 4.0% in the 1st quarter. Vanguard Group Inc. now owns 273,150 shares of the company’s stock valued at $1,335,000 after acquiring an additional 10,400 shares during the period. 4.30% of the stock is owned by institutional investors and hedge funds.
Armata Pharmaceuticals Company Profile (Get Rating)
Armata Pharmaceuticals, Inc, a clinical-stage biotechnology company, focuses on the development of targeted bacteriophage therapeutics for antibiotic-resistant infections worldwide. It develops its products using its proprietary bacteriophage-based technology. The company's product candidates include AP-SA02 for the treatment of Staphylococcus aureus bacteremia; AP-PA02 for Pseudomonas aeruginosa; and AP-PA03 for the treatment of pneumonia.
- Get a free copy of the StockNews.com research report on Armata Pharmaceuticals (ARMP)
- MarketBeat: Week in Review 5/16 – 5/20
- 3 Retailers That Defied First Quarter Headwinds
- Rapid7: Could Be Profitable in FY 2022 Despite Bear Market
- Will John Deere’s Earnings Help to Calm the Markets?
- Lowe’s Companies Has Not Bottomed
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Armata Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Armata Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.